Table 3. Composition of the prognosis tissue microarray containing 12,427 prostate cancer specimens.
| No. of patients (%) | ||
|---|---|---|
| Study cohort on TMA | Biochemical relapse among categories | |
| (n = 12427) | ||
| Follow-up (mo) | ||
| n | 11665 (93.9%) | 2769 (23.7%) |
| Mean | 48.9 | − |
| Median | 36.4 | − |
| Age (y) | ||
| ≤ 50 | 334 (2.7%) | 81 (24.3%) |
| 51–59 | 3061 (24.8%) | 705 (23.0%) |
| 60–69 | 7188 (58.2%) | 1610 (22.4%) |
| ≥ 70 | 1761 (14.3%) | 370 (21.0%) |
| Pretreatment PSA (ng/ml) | ||
| < 4 | 1585 (12.9%) | 242 (15.3%) |
| 4–10 | 7480 (60.9%) | 1355 (18.1%) |
| 10–20 | 2412 (19.6%) | 737 (30.6%) |
| > 20 | 812 (6.6%) | 397 (48.9%) |
| pT category (AJCC 2002) | ||
| pT2 | 8187 (66.2%) | 1095 (13.4%) |
| pT3a | 2660 (21.5%) | 817 (30.7%) |
| pT3b | 1465 (11.8%) | 796 (54.3%) |
| pT4 | 63 (0.5%) | 51 (81.0%) |
| Gleason grade | ||
| ≤ 3+3 | 2983 (24.1%) | 368 (12.3%) |
| 3+4 | 6945 (56.2%) | 1289 (18.6%) |
| 4+3 | 1848 (15.0%) | 788 (42.6%) |
| ≥ 4+4 | 584 (4.7%) | 311 (53.3%) |
| pN category | ||
| pN0 | 6970 (91.0%) | 1636 (23.5%) |
| pN+ | 693 (9.0%) | 393 (56.7%) |
| Surgical margin | ||
| Negative | 9990 (81.9%) | 1848 (18.5%) |
| Positive | 2211 (18.1%) | 853 (38.6%) |
NOTE: Numbers do not always add up to 12,427 in the different categories because of cases with missing data. Abbreviation: AJCC, American Joint Committee on Cancer.